ID   ALVA-31
AC   CVCL_4737
SY   ALVA 31; ALVA31; American Lake VA-31
DR   BTO; BTO_0003850
DR   BioSample; SAMN03151889
DR   cancercelllines; CVCL_4737
DR   Wikidata; Q54749373
RX   CelloPub=CLPUB00698;
RX   PubMed=7681207;
RX   PubMed=8561862;
RX   PubMed=11304728;
RX   PubMed=12725112;
RX   PubMed=20143388;
WW   Info; ICLAC; -; https://iclac.org/wp-content/uploads/Cross-Contaminations_v13_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a PC-3 derivative (PubMed=11304728; PubMed=20143388; CelloPub=CLPUB00698). Originally thought to originate from the tumor mass removed during a radical prostatectomy in a patient with well differentiated, stage B2, adenocarcinoma of the prostate.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00173.
CC   Population: Caucasian.
CC   Doubling time: ~26 hours (PubMed=7681207); 23 hours (PubMed=8561862).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (PubMed=11304728).
CC   Derived from site: Metastatic; Bone; UBERON=UBERON_0002481.
ST   Source(s): PubMed=11304728
ST   Amelogenin: X
ST   D13S317: 11
ST   D18S51: 15
ST   D21S11: 29,31.2
ST   D3S1358: 16
ST   D5S818: 13,14
ST   D7S820: 8,11,12
ST   D8S1179: 13
ST   FGA: 24
ST   vWA: 17
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0035 ! PC-3
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 28
//
RX   CelloPub=CLPUB00698;
RA   van Bokhoven, Adrie
RT   "Models for prostate cancer. Molecular characterization and critical
RT   appraisal of human prostate carcinoma cell lines.";
RL   Thesis PhD (2004); Katholieke Universiteit Nijmegen; Nijmegen; Netherlands.
//
RX   PubMed=7681207; DOI=10.1002/pros.2990220202;
RA   Loop, Steven M.
RA   Rozanski, Thomas A.
RA   Ostenson, Richard C.
RT   "Human primary prostate tumor cell line, ALVA-31: a new model for
RT   studying the hormonal regulation of prostate tumor cell growth.";
RL   Prostate 22:93-108(1993).
//
RX   PubMed=8561862; DOI=10.1002/(SICI)1098-2744(199601)15:1<18::AID-MC4>3.0.CO;2-O;
RA   Mehta, Parmender P.
RA   Lokeshwar, Balakrishna L.
RA   Schiller, Paul C.
RA   Bendix, Marcelo V.
RA   Ostenson, Richard C.
RA   Howard, Guy A.
RA   Roos, Bernard A.
RT   "Gap-junctional communication in normal and neoplastic prostate
RT   epithelial cells and its regulation by cAMP.";
RL   Mol. Carcinog. 15:18-32(1996).
//
RX   PubMed=11304728; DOI=10.1002/pros.1045;
RA   van Bokhoven, Adrie
RA   Varella-Garcia, Marileila
RA   Korch, Christopher T.
RA   Hessels, Daphne
RA   Miller, Gary J.
RT   "Widely used prostate carcinoma cell lines share common origins.";
RL   Prostate 47:36-51(2001).
//
RX   PubMed=12725112; DOI=10.1385/1-59259-372-0:21;
RA   Russell, Pamela J.
RA   Kingsley, Elizabeth A.
RT   "Human prostate cancer cell lines.";
RL   Methods Mol. Med. 81:21-39(2003).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis, Amanda
RA   Theodosopoulos, George
RA   Atkin, Isobel
RA   Drexler, Hans Gunther
RA   Kohara, Arihiro
RA   MacLeod, Roderick A.F.
RA   Masters, John R.W.
RA   Nakamura, Yukio
RA   Reid, Yvonne A.
RA   Reddel, Roger Robert
RA   Freshney, Robert Ian
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//